News
Mabswitch Receives Prestigious SBIR Phase 1 Award from National Cancer Institute for Innovative SaefCAR Immunotherapy Project
Los Angeles, CA – Mabswitch Inc, a pioneering biotechnology company at the forefront of cutting-edge cancer immunotherapies, is proud to announce that it has been awarded a Small Business Innovation Research (SBIR) Phase 1 grant by the National Cancer Institute (NCI). This grant will support Mabswitch’s groundbreaking project, titled “SaefCAR: Read more…